(Q39208364)

10 September 2017

HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts (English)

1 reference

10 September 2017

1 reference

angiogenesis inhibitor

1 reference

1 reference

Joseph Hartwich

1

1 reference

10 September 2017

W Shannon Orr

2

1 reference

10 September 2017

Catherine Y Ng

3

1 reference

10 September 2017

Yunyu Spence

4

1 reference

10 September 2017

Christopher Morton

5

1 reference

10 September 2017

Andrew M Davidoff

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

Journal of Pediatric Surgery

10 September 2017

1 reference

10 September 2017

48

1 reference

10 September 2017

1

1 reference

10 September 2017

39-46

1 reference

describes a project that uses

10 September 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3601778/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Distinct response of experimental neuroblastoma to combination antiangiogenic strategies

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601778

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23331791

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.JPEDSURG.2012.10.016

1 reference

release_mnjhqla3uzczdjhfgygyupu5kq

10 September 2017

0 references

1 reference

10 September 2017

1 reference